RFB002A ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
166弾性線維性仮性黄色腫1

166. 弾性線維性仮性黄色腫


臨床試験数 : 16 薬物数 : 27 - (DrugBank : 5) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 28
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2013-001421-55-FR
(EUCTR)
13/06/201322/09/2015An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. - ECLIPSEAn open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases. - ECLIPSE Choroidal neovascularization not related to wet Age-related macular degeneration (wAMD), pathologic myopia (PM)or Pseudoxanthoma elasticum (PXE), as well as in Macular Edema (ME) not related to Retinal Vein Occlusion (RVO) or Diabetic macular edema (DME) and other ocular neovascularization and/or complication such as Rubeosis Iridis and Neovacular Glaucoma and Proliferative Diabetic Retinopathy requiring Vitrectomy
MedDRA version: 18.0;Level: HLGT;Classification code 10047060;Term: Retina, choroid and vitreous haemorrhages and vascular disorders;System Organ Class: 10015919 - Eye disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11]
Trade Name: Lucentis
Product Name: Lucentis
Product Code: RFB002A
INN or Proposed INN: RANIBIZUMAB
Novartis Pharma S.A.SNULLNot RecruitingFemale: yes
Male: yes
500Phase 3France